LFB S.A. Announces That First Patient Has Begun Treatment With New Coagulation Factor VIIa (Recombinant) In Global Phase 3 Clinical Trial In Hemophilia A And B With Inhibitors
5/14/2014 10:16:04 AM
FRAMINGHAM, Mass.--(BUSINESS WIRE)--LFB SA, through its U.S. subsidiary, announced today that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by